InMed Pharmaceuticals Inc. Common Shares closed at $8.75 on Nov 4, up 420.83% — matching its 52-week closing high. Volume of 24.1K shares was 0.37× its 20-day average (below normal).
Split-adjusted performance: +557.9% over one month, +1104.6% over six months, +373.0% over one year.
Short interest was 6.6K shares at the Oct 15 settlement, down 80.5% from the prior report (0.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INMInMed Pharmaceuticals | $8.75 | +420.83% | +1104.6% | — | — | — | $48.1M | |
| GANXGain Therapeutics | $1.11 | −3.48% | −41.9% | — | — | — | $48.4M | Compare |
| CNTBConnect Biopharma Holdings Limited | $0.7805 | +0.83% | −68.5% | +5666.7% | −624.4% | — | $49.2M | Compare |
| HYPDHyperion DeFi | $3.07 | +0.66% | −15.7% | — | 4009.1% | — | $46.7M | Compare |
| IBIOiBio | $0.8000 | −2.85% | −54.8% | −100.0% | — | — | $51.4M | Compare |
| ANVSAnnovis Bio | $1.21 | +11.01% | −49.6% | — | — | — | $51.6M | Compare |
| BMEABiomea Fusion | $0.6119 | −1.91% | −61.8% | — | — | — | $44.4M | Compare |
| ATNMActinium Pharmaceuticals | $1.41 | +0.71% | +13.7% | — | 79.7% | 3.9 | $44.3M | Compare |
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | Compare |
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
